Bridgefront Capital’s NeoGenomics NEO Stock Holding History

Bridgefront Capital’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-41,357	Closed	-$302K	–	743
2025 Q2	$302K	Buy	+41,357	New	+$334K	0.08%	428
2024 Q4	–	Sell	-12,265	Closed	-$181K	–	718
2024 Q3	$181K	Sell	12,265 -1,190	-9%	-$18.6K	0.07%	466
2024 Q2	$187K	Buy	+13,455	New	+$191K	0.08%	419
2024 Q1	–	Sell	-10,566	Closed	-$171K	–	505
2023 Q4	$171K	Sell	10,566 -4,568	-30%	-$74.7K	0.13%	312
2023 Q3	$186K	Buy	+15,134	New	+$225K	0.13%	324
2021 Q4	–	Sell	-4,677	Closed	-$226K	–	405
2021 Q3	$226K	Buy	+4,677	New	+$217K	0.24%	215
2021 Q2	–	Sell	-6,842	Closed	-$330K	–	801
2021 Q1	$330K	Buy	+6,842	New	+$356K	0.1%	392

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bridgefront Capital's NEO Position: Q3 2025 in Review

Bridgefront Capital sold out of NeoGenomics (NEO) in Q3 2025, closing a stake of 41,357 shares — an estimated $302K sold.

Bridgefront Capital first reported a position in NEO in Q1 2021 and held it in 7 quarters. The position peaked at $330K in Q1 2021. 254 funds tracked by Wall St. Rank hold NEO as of Q3 2025.

Bridgefront Capital reported no remaining NeoGenomics position as of Q3 2025 after selling out during the quarter.
Bridgefront Capital sold 41,357 NeoGenomics shares in Q3 2025, an estimated $302K.
Bridgefront Capital first reported a position in NeoGenomics in Q1 2021 and held it in 7 quarters.
Bridgefront Capital's NeoGenomics position peaked at $330K in Q1 2021.
254 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2025.

Based on Bridgefront Capital's 13F filing for Q3 2025, filed 14 Nov 2025.